NeuroBo Pharmaceuticals, Inc. is a clinical stage biotechnology company dedicated to the development and commercialization of multimodal, disease-modifying therapies targeting neurodegenerative and cardiometabolic diseases. The company operates in the biotechnology sector, focusing on innovative treatments that address significant unmet medical needs. NeuroBo's pipeline includes three therapeutic programs aimed at pain indications, neurodegenerative diseases, and dyslipidemias. The lead drug candidate, NB-01, has demonstrated significant efficacy in reducing pain symptoms associated with Peripheral Diabetic Neuropathy (PDN) in Phase 2 clinical trials, showcasing a superior safety profile compared to existing treatments. Another promising candidate, NB-02, has shown neuroprotective properties in preclinical studies, with a multimodal mechanism of action that includes inhibition of neuroinflammation and oxidative stress. NeuroBo primarily serves patients suffering from chronic and debilitating conditions, aiming to improve their quality of life through advanced therapeutic solutions. The company generates revenue through partnerships, licensing agreements, and potential future sales of its drug candidates upon regulatory approval.

Keywords: biotechnology, neurodegenerative, cardiometabolic, multimodal therapies, pain management, dyslipidemias, Peripheral Diabetic Neuropathy, neuroprotection, clinical trials, innovative treatments.